LUND, Sweden, Nov. 23, 2021 /PRNewswire/ -- Immunovia AB
(publ) ("Immunovia"), a diagnostic company that develops and sells
highly accurate blood tests for the early detection of cancer,
honored World Pancreatic Cancer Day - this year on November 18th - by hosting a Grand
Opening celebration at their offices in Marlborough, Massachusetts.
World Pancreatic Cancer Day occurs on the third Thursday in
November each year for people around the globe to work to raise
awareness of the risk factors, signs, and symptoms of pancreatic
cancer - one of the deadliest cancer types. This year Immunovia
celebrated World Pancreatic Cancer Day by a grand opening of
Immunovia, Inc., that recently launched and exclusively offers the
first available blood test for early detection of pancreatic cancer
in the US. Nearly 150 people attended the event, including health
care professionals, patient representatives, and local
State Senator Jamie Eldridge
(D-Acton) started the evening
providing an official citation from the State Senate of
Massachusetts to Immunovia, Inc.
in recognition of the "momentous occasion of your grand opening",
and by highlighting how important it is to have an early detection
test for pancreatic cancer available. The Mayor of Marlborough, Mayor Arthur
Vigeant, cut the ribbon for the new laboratory.
Representatives from various patient organizations, including
DetecTogether, FORCE, The Lustgarten Foundation, The National
Pancreas Foundation, the UMASS Pancreatic Cancer Alliance, and
PanCAN Boston all spoke briefly about their organizations.
As part of this celebration, Immunovia, Inc. offered discounted
test pricing to individuals who took the opportunity to take the
blood test on the premises. An independent primary care physician
was also onsite to counsel patients about their risk for developing
pancreatic cancer and how to manage that risk.
As Geoffrey M. Burns M.D., Fellow
of the American Academy of Family Physicians, one of the physicians
attending the event, stated "The vibe of the evening reminded me of
my humanitarian missions where despite trauma there are both lots
of feelings of hope present and strong collaborative efforts of
everyone pulling together to help."
For more information, please contact:
Patrik Dahlen, CEO Immunovia
Tel: +46 73 376 76 64
Immunovia AB is a diagnostic company that is developing and
commercializing highly accurate blood tests for the early detection
of cancer based on Immunovia's proprietary test platform
called IMMray™. Tests are based on antibody biomarker
microarray analysis using advanced machine-learning and
bioinformatics to single-out a set of relevant biomarkers that
indicate a certain disease. Thus, forming a unique "disease
The company was founded in 2007, based on cancer studies and
ground-breaking research in the Department of Immuntechnology at
Lund University and CREATE Health
Cancer Center, Sweden.
The first product, IMMray™ PanCan-d, is undergoing clinical
evaluation in some of the world's largest clinical studies for
high risk groups in pancreatic cancer, PanFAM-1, PanSYM-1 and
In 2017, Immunovia, Inc. was established in Marlborough, Massachusetts, USA. The IMMray™
PanCan-d test, the first blood-based test dedicated to the early
detection of pancreatic cancer on the market, is offered as a
laboratory developed test (LDT) exclusively through Immunovia, Inc.
For more information see: www.immunoviainc.com.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
information was brought to you by Cision http://news.cision.com
The following files are available for download: